| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/03/2022 | 239.79% | Ladenburg Thalmann | → $2 | Initiates Coverage On | → Buy |
| 06/23/2022 | 409.68% | Goldman Sachs | $11 → $3 | Maintains | Neutral |
| 08/20/2021 | 579.58% | Benchmark | → $4 | Initiates Coverage On | → Speculative Buy |
Alterity Therapeutics Questions & Answers
The latest price target for Alterity Therapeutics (NASDAQ: ATHE) was reported by Ladenburg Thalmann on August 3, 2022. The analyst firm set a price target for $2.00 expecting ATHE to rise to within 12 months (a possible 239.79% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Alterity Therapeutics (NASDAQ: ATHE) was provided by Ladenburg Thalmann, and Alterity Therapeutics initiated their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alterity Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alterity Therapeutics was filed on August 3, 2022 so you should expect the next rating to be made available sometime around August 3, 2023.
While ratings are subjective and will change, the latest Alterity Therapeutics (ATHE) rating was a initiated with a price target of $0.00 to $2.00. The current price Alterity Therapeutics (ATHE) is trading at is $0.59, which is within the analyst's predicted range.